◆ NeutralSPRY
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
GlobeNewswire Inc.·
Rosen Law Firm is encouraging investors who purchased securities of ARS Pharmaceuticals (SPRY) between March 9, 2026 and June 24, 2026 to join a class action lawsuit. The firm alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product (neffy) through CVS Caremark, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.
Read Full Article at GlobeNewswire Inc. →